The estimated Net Worth of Elyse Stock is at least $2.66 Million dollars as of 10 January 2022. Elyse Stock owns over 937 units of Biohaven Ltd stock worth over $191,959 and over the last 5 years he sold BHVN stock worth over $0. In addition, he makes $2,467,420 as Chief Medical Officer at Biohaven Ltd.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Elyse Stock BHVN stock SEC Form 4 insiders trading
Elyse has made over 11 trades of the Biohaven Ltd stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 937 units of BHVN stock worth $33,470 on 10 January 2022.
The largest trade he's ever made was exercising 36,966 units of Biohaven Ltd stock on 12 June 2020 worth over $957,419. On average, Elyse trades about 7,898 units every 58 days since 2019. As of 10 January 2022 he still owns at least 5,374 units of Biohaven Ltd stock.
You can see the complete history of Elyse Stock stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Elyse Stock biography
Dr. Elyse Stock M.D. serves as Chief Medical Officer of the Company., since August 2019. Prior to this, from June 2017 to August 2019, she served as our chief of portfolio strategy and development. Prior to her time at the Company, she served 19 years at BMS developing numerous experimental agents across multiple therapeutic areas including neuroscience, oncology, immunology and cardiovascular. Dr. Stock completed her residency at Payne Whitney Clinic, Cornell Medical Center and her fellowship in Child and Adolescent Psychiatry at Children's Hospital National Medical Center in Washington D.C. She earned her medical degree at New York University School of Medicine.
What is the salary of Elyse Stock?
As the Chief Medical Officer of Biohaven Ltd, the total compensation of Elyse Stock at Biohaven Ltd is $2,467,420. There are 5 executives at Biohaven Ltd getting paid more, with Vlad Coric having the highest compensation of $6,787,630.
How old is Elyse Stock?
Elyse Stock is 62, he's been the Chief Medical Officer of Biohaven Ltd since 2019. There are 3 older and 12 younger executives at Biohaven Ltd. The oldest executive at Biohaven Ltd is Julia Gregory, 67, who is the Independent Director.
What's Elyse Stock's mailing address?
Elyse's mailing address filed with the SEC is C/O BIOHAVEN PHARMACEUTICALS, INC., 215 CHURCH STREET, NEW HAVEN, CT, 06510.
Insiders trading at Biohaven Ltd
Over the last 8 years, insiders at Biohaven Ltd have traded over $8,186,598,135 worth of Biohaven Ltd stock and bought 8,852,002 units worth $137,738,037 . The most active insiders traders include Robert J Hugin, John W Childs, and Declan Doogan. On average, Biohaven Ltd executives and independent directors trade stock every 14 days with the average trade being worth of $2,840,776. The most recent stock trade was executed by John W Childs on 18 July 2024, trading 28,400 units of BHVN stock currently worth $1,013,028.
What does Biohaven Ltd's logo look like?
Complete history of Elyse Stock stock trades at Biohaven Ltd
Biohaven Ltd executives and stock owners
Biohaven Ltd executives and other stock owners filed with the SEC include:
-
Vlad Coric,
Chief Executive Officer, Director -
William Jones,
Chief Commercial Officer, Migraine and Common Diseases -
Charles Conway,
Chief Scientific Officer -
Kimberly Gentile,
Senior Vice President - Clinical Operations -
James Engelhart,
Chief Financial Officer, Treasurer -
Elyse Stock,
Chief Medical Officer -
John Tilton,
Chief Commercial Officer, Rare and Orphan Diseases -
Dr. Vladimir Coric M.D.,
Chairman, CEO & Pres -
William Jones M.B.A.,
Chief Commercial Officer of Migraine & Common Diseases -
Julia Gregory,
Independent Director -
John Childs,
Director -
Gregory Bailey,
Director -
Dr. Elyse Stock M.D.,
Chief Medical Officer -
Kimberly Gentile,
Sr. VP of Clinical Operations -
Robert Berman,
Lead - Special Projects and Medical Oversight -
Robert Hugin,
Director -
Michael Heffernan,
Director -
Thomas Lynch,
Chairman of the Board -
Clifford Bechtold M.S.,
Pres & GM of Biohaven Ireland and Chief Compliance Officer -
Wendy Goss,
Exec. Admin. Assistant -
Dr. Charles Conway,
Chief Scientific Officer -
George C. Clark,
VP & Chief Accounting Officer -
Matthew DeLawder,
Director of Accounting -
Matthew Buten,
Chief Financial Officer -
Albert Cha,
Director -
Robert Repella,
Director -
Eric Aguiar,
-
Biotech Inc. Portage,
-
Declan Doogan,
-
Irina Antonijevic,
-
Kishan Mehta,
-
George C. Clark,
VP, Chief Accounting Officer -
Matthew Buten,
Chief Financial Officer -
Pharmaceutical Holding Co L...,
-
Bruce Car,
Chief Scientific Officer